2 Day Virtual Process Validation Training Course: FDA and EU Annex 15 Qualifications and Validation - Enhance your Understanding of the Utilization of Process Validation and Phase 1, 2 and 3

News provided by

Nov 15, 2023, 05:45 ET

DUBLIN, Nov. 15, 2023 /PRNewswire/ -- The "Process Validation Training Course (FDA and EU Annex 15: Qualifications and Validation)" training has been added to ResearchAndMarkets.com's offering.

This seminar will provide a channel to enhance understanding of the utilization of process validation and Phase 1, 2 and 3, where their guidance blend and where they remain distinct. In particular, Stage 3 continued process verification, will be reviewed in detail: where does it begin; what is included; and, when does it end.

This training program will illustrate how these two different concepts are integrated (Phase 1, 2, and 3 vs. Stages 1, 2, and 3) and where do they merge. Attendees will learn if they exist independently of each other or do they complement each other to enhance, build and provide a product.

The new Process Validation Guideline/Practice incorporate elements of Process Validation as early as the Research and Development phase, and continues onward through Technology Transfer, into the Phase 1 IND Clinical Trial manufacturing phase, and ultimately into Phase 2 and 3, and then commercial manufacturing.

Each facility, whether producing small or large molecules requires both an overall Site Validation Plan as well as specific validation plans to manage the multiplicity of validations required to confirm the successful manufacture of each of its products.

This two day, interactive Seminar which provides a conduit to enhance your understanding of the Continued Process Verification, will be reviewed in detail: where does it begin; what is included; and, when does it end.

Common questions asked by the users of Process Validation include:

How does one integrate these two different concepts (Phase 1, 2, and 3 vs. Stages 1, 2, and 3) and where do they merge?
Do they exist independently of each other or do they complement each other to enhance, build and provide a product that neither alone could. Questions that may arise include where are cGMPs initiated?
To what extent must they be used? Since Stage 3 extends through commercial batch manufacturing, what happens to Phase 3?
Does it follow along or with Stage 3?
These questions will be addressed within Stage 2 as presented here and include utilization of Process Validation and Phase 1, 2 and 3, where their Guidance blend and where they remain distinct. In particular, Stage 3.

Seminar Objectives

Why these FDA Guidance/EU Guidelines for Industry - Process Validation is so important to the pharmaceutical and biotechnology industry.
What FDA segments are included and excluded within the "NEW" Process Validation.
Where does the Process Validation commence.
What are the Three Stages and Where They Apply within the NEW Process Validation.
How Stage 1 integrates with Phase 1.
The Validation approaches that are included within this Guidance document.
The Statutory and Regulatory Requirements for Process Validation.
An Introduction Phase 1 Guidance for Industry and Its Application within the "NEW" Process Validation.
The Phase 1 Investigational Drug Requirements - What is and What is NOT Required.
General Considerations for Process Validation - Stage 2 Process Qualification.
Regulatory Strategies for Phase 2 and 3 and their Incorporation within Stages 1 and 2.
General Considerations for Process Validation - Stage 3 Continued Process Verification.
A Review of EU Annex 15 and its Comparison to FDA's Process Validation Guidance.

Who Should Attend:

Quality Assurance Departments
Quality Control Departments
Regulatory Compliance Departments
Validation Teams
Product Development Teams
Project Management Teams
Engineering Departments
Manufacturing Departments
Contract Manufacturers
Internal Auditors
Facilities Professionals

DAY 1

Lecture 1: Process Validation - Overview

Introduction, Goals and Objectives, Definitions
Its Importance within the Industry

Lecture 2: Phases and Stages

Interaction of the Three Stages with Process Validation
How the two different concepts are integrated (Phase 1, 2, and 3 vs. Stages 1, 2, and 3)
Where do they merge?
Do they exist independently of each other?
Do they complement each other to enhance, build and provide a product?

Lecture 3: Phase 1, 2 and 3

Validation Approaches, cGMPs in Clinical Supply
Manufacture, Special Manufacturing Situations within Phase 1
The Requirements of Phase 1 Investigational Drug Requirements
Regulatory Strategies for Phase 2 and 3 and their Incorporation within Stages 1 and 2

Day 2

Lecture 4: Stages 2 and 3

General Considerations for Process Validation - Stage 2 Process Qualifications
Special Considerations for Process Validation - Stage 2
General Considerations for Process Validation - Stage 3 Continued Process Verification

Lecture 5: EU Annex 15

A Review of EU Annex 15
Comparison to FDA's Process Validation Guidance

Lecture 6: Process Performance Qualification (PPQ) Batches

Concurrent Release of PPQ Batches
Role of SOP in the company QM System
How to deal with the established 3 batch approach?

Lecture 7: Analytical Methodology and Process Validation and Warning Letter examples

Speaker

Joy McElroy offers 20 years of experience as a consultant and over 25 years' total experience in the pharmaceutical and biotech industries in quality control, clinical settings, good manufacturing practice (GMP) auditing as well as validation engineering.

McElroy specializes in equipment qualification, cleaning validation, sterilization, environmental monitoring, GMP compliance auditing, good documentation practices, GMP and good laboratory practice training. She has written and executed equipment qualification and validation protocols for numerous companies. Joy is co-owner of Maynard Consulting Company.

For more information about this training visit https://www.researchandmarkets.com/r/dhj6k4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets